Score Overview
Explore the 2021 public Archive ranking →
Where Biomarin Pharmaceutical Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- BMRN
2005: 92.9% · 2021: 7.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 59.87 | — |
1 Year2025-09-29 | $ 54.02 | 10.83% |
5 Years2021-09-29 | $ 76.79 | -22.03% |
10 Years2016-09-29 | $ 92.78 | -35.47% |
20 Years2006-09-29 | $ 14.23 | 320.73% |
All Time1999-07-23 | $ 13.13 | 356.15% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time1999-07-23 |
|---|---|---|---|---|---|---|
| Price | $ 59.87 | $ 54.02 | $ 76.79 | $ 92.78 | $ 14.23 | $ 13.13 |
| Return | — | 10.83% | -22.03% | -35.47% | 320.73% | 356.15% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.40B | $ 72M | $ 874M |
| 2025 | $ 3.22B | $ 348M | $ 1.56B |
| 2024 | $ 2.85B | $ 426M | $ 1.13B |
| 2023 | $ 2.41B | $ 167M | $ 1.07B |
| 2022 | $ 2.09B | $ 141M | $ 1.29B |
| 2021 | $ 1.84B | -$ 64M | $ 1.01B |
| 2020 | $ 1.86B | $ 854M | $ 1.06B |
| 2019 | $ 1.70B | -$ 23M | $ 753M |
| 2018 | $ 1.49B | -$ 77M | $ 1.08B |
| 2017 | $ 1.31B | -$ 117M | $ 1.39B |
| 2016 | $ 1.11B | -$ 630M | $ 789M |
| 2015 | $ 889M | -$ 171M | $ 592M |
| 2014 | $ 749M | -$ 133M | $ 945M |
| 2013 | $ 548M | -$ 176M | $ 784M |
| 2012 | $ 500M | -$ 114M | $ 450M |
| 2011 | $ 441M | -$ 53M | $ 195M |
| 2010 | $ 376M | $ 205M | $ 274M |
| 2009 | $ 324M | $ 300M | |
| 2008 | $ 296M | $ 30M | $ 559M |
| 2007 | $ 121M | -$ 15M | $ 585M |
| 2006 | $ 84M | -$ 28M | $ 288M |
| 2005 | $ 25M | -$ 74M | $ 47M |
| 2004 | $ 18M | -$ 187M | $ 48M |
| 2003 | $ 12M | -$ 75M | $ 206M |
| 2002 | $ 13M | -$ 77M | $ 73M |
| 2001 | $ 11M | -$ 67M | $ 131M |
| 2000 | $ 9M | -$ 37M | $ 40M |
| IPO1999 | $ 5M | -$ 28M | $ 62M |
Biomarin Pharmaceutical Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 1.86B to $ 3.22B and net income declined from $ 854M to $ 348M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 889M to $ 3.22B and net income went from -$ 171M to $ 348M. Revenue increased in 9 of those 10 years; net income in 7.
Biomarin Pharmaceutical Inc currently holds a 20-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.
Membership
Continue BMRN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
